|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations inlung adenocarcinomas otherwise negative for such alterations by othergenomic testing approaches 显示文摘 | Drilon A Wang L Arcila ME | 2015 | Clin Cancer Res2015，21，16： | 1 |
| 2 | Response to cabozantinib in patients with RET fusion-positive lung adenocareinomas显示文摘 | Drilon A Wang L Hasanovic A | 2013 | Cancer Diseov2013，3，6： | 1 |
| 3 | Response to cabozantinib inpatients with RET fusion-positive lung adenocarcinomas 显示文摘 | Drilon A Wang L Hasanovic A | 2013 | CancerDiscov2013，3，6： | 1 |
| 4 | Screening for RET and ROS1 fusions in an enriched co- hort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in tar- geted therapy trials显示文摘 | Dela Cruz Drilon AE Wang L Hasanovic A | 2013 | J Clin Oncol2013，31，15： | 1 |
| 5 | Response to Cabozantinib in patients with RET fusion - positive lung adenocarcinomas 显示文摘 | Drilon A Wang L Hasanovic A | 2013 | Cancer Discov2013，3，6： | 1 |
| 6 | Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine- DNA methyltransferase 显示文摘 | Zauderer MG Drilon A Kadota K | 2014 | Lung Cancer2014，86，2： | 1 |
| 7 | Squamous-cell carcinomas of the lung: emerging biology, controver- sies, and the promise of targeted ther- apy显示文摘 | Drilon A Rekhtman N Ladanyi M | 2012 | Lancet Oncol2012，13，41： | 1 |
| 8 | Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas 显示文摘 | Drilon A Wang L Hasanovic A | 2013 | Cancer discovery2013，3，6： | 1 |
| 9 | Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas显示文摘 | Drilon A Wang L Hasanovic A | 2013 | Cancer Discov2013，3，6： | 1 |
| 10 | KRAS mutations predict sensitivity to Pemetrexed-based chemotherapy显示文摘 | Levy B Drilon A1 Chachoua A | | 0，，04： | 1 |
| 11 | Squamous-cell carcino- mas of the lung:emerging biology, controversies, and the promise of targeted therapy显示文摘 | Drilon A Rekhtman N Ladanyi M | 2012 | Lancet Onco12012，13，10： | 1 |
| 12 | Broad,hybrid capture-based nextgeneration sequencing identifies actionable genomic alterations in 'driver-negative' lung adenocarcinomas显示文摘 | Drilon A Wang L Arcila ME | 2015 | Clin Cancer Res2015，，： | 1 |
| 13 | Squamous-cell carci- nomas of the lung: emerging biology, controversies, and the promise of targeted therapy显示文摘 | Drilon A Rekhtman N Ladanyi M | 2012 | Lancet Oneol2012，13，0： | 1 |
| 14 | Response toCabozantinib in Patients with RET Fusion-Positive Lung Adeno-carcinomas 显示文摘 | DRILON A WANG L HASANOVIC A | 2013 | Cancer2013，3，6： | 1 |
| 15 | Response to MET inhibitors in patients with stage Ⅳ lung adenocarcinomas harboring MET mutations causing exon 14 skipping显示文摘 | Paik PK Drilon A Fan PD | 2015 | Cancer Discov2015，5，8： | 1 |
| 16 | Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping显示文摘 | Paik PK Drilon A Fan PD | 2015 | Cancer Discov2015，5，8： | 1 |
| 17 | Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy 显示文摘 | Drilon A Rekhtman N Ladanyi M | 2012 | Lancet Oncol2012，13，10： | 1 |
| 18 | Response to cabozantinib in patients with ret fusion-positive lung adenocarcinomas显示文摘 | Drilon A Wang L Hasanovic A | 2013 | CancerDiscov2013，3，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员